On the other hand, several studies have suggested that epigenetic changes, defined as heritable changes to gene expression without affecting DNA sequence, can regulate Keap1/Nrf2 activity [6]; DNA methylation, histone modifications, non-coding RNAs, and chromatin remodeling are implicated in the regulation of this nuclear factor; thus, targeting these epigenetic changes might be useful for modulating the Keap1/Nrf2 signaling pathway and, eventually, for treating liver disease [7]. This evidence concerns the gene KEAP1 and liver disorder.